- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| 27.03. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 4 | SGX Company Announcements | ||
| 12.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 07.02. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 28.01. | S&P Global upgrades Biocon Biologics ratings | 5 | Times of India | ||
| 28.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 15.01. | Biocon Raises Rs 4,150 Crore Via QIP, To Buy Viatris Stake In Biocon Biologics | 20 | The Free Press Journal | ||
| 14.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | - | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ACQUISITION OF BBL SHARES AND ALLOTMENT OF BL EQUITY SHARES | 1 | SGX Company Announcements | ||
| 06.01. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 23.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 13.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 11.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 08.12.25 | Viatris sells Biocon Biologics stake for $815 million in cash and equity deal | 38 | Seeking Alpha | ||
| 06.12.25 | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 873 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ANALYST CALL INTIMATION SUBMITTED BY BIOCON LIMITED | 3 | SGX Company Announcements | ||
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 3 | SGX Company Announcements | ||
| 06.12.25 | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 02.12.25 | Biocon Biologics settles with Amgen to launch Denosumab Biosimilars in Europe, rest of the world | 10 | ZEE Business |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 86,52 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARCELLX | 114,80 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 18,050 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| ONCONETIX | 1,210 | 0,00 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson | ||
| AMYLYX PHARMACEUTICALS | 17,320 | 0,00 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 33,520 | 0,00 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| BICARA THERAPEUTICS | 21,980 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| ENLIVEN THERAPEUTICS | 45,620 | 0,00 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| QIAGEN | 35,185 | +0,44 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,330 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 25,650 | 0,00 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| CULLINAN THERAPEUTICS | 15,210 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| ERASCA | 17,360 | 0,00 % | What's Driving Erasca (ERAS)'s Nearly 355% YTD Return | ||
| VERA THERAPEUTICS | 40,940 | 0,00 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| SEPTERNA | 24,830 | 0,00 % | Septerna, Inc.: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results | Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R... ► Artikel lesen |
Das Unternehmen BIOCON BIOLOGICS GLOBAL PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 99,79 Euro und damit +0,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.